


SUBSTITUTE FORM PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 06501-058001
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (IF KNOWN)  <b>09/529962</b>
INTERNATIONAL APPLICATION NO. PCT/JP98/04772	INTERNATIONAL FILING DATE October 21, 1998	PRIORITY DATE CLAIMED October 22, 1997	
TITLE OF INVENTION METHOD FOR SCREENING FULL-LENGTH CDNA CLONES			
APPLICANT(S) FOR DO/EO/US Toshio Ota, Tetsuo Nishikawa, Asaf Salamov and Takao Isogai			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern other documents or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p> <p><input type="checkbox"/></p>			

"Express Mail" mailing label number EL445372039 USDate of Deposit April 20, 2000

I hereby certify that this paper or fee is being deposited with  
the United States Postal Service "Express Mail Post Office to  
Addressee" service under 37 CFR 1.10 on the date indicated above  
and is addressed to the Assistant Commissioner For Patents,  
Washington, D.C. 20231

Samantha Bell  
Samantha Bell

U.S. APPLICATION NO. (IF KNOWN) <b>097529962</b>		INTERNATIONAL APPLICATION NO. PCT/JP98/04772	ATTORNEY'S DOCKET NUMBER 06501-058001	
17. <input checked="" type="checkbox"/> The following fees are submitted:			CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)):				
Search report has been prepared by the EPO or JPO ..... \$840			\$840.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) .. \$670				
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).... \$690				
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$970				
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2) to (4) ..... \$96				
ENTER APPROPRIATE BASIC FEE AMOUNT			\$840.00	
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(e)).			\$0.00	
Claims	Number Filed	Number Extra	Rate	
Total Claims	7 - 20		x \$18	\$0.00
Independent Claims	2 - 3		x \$78	\$0.00
Multiple Dependent Claims(s) (if applicable)			+ \$260	\$0.00
TOTAL OF ABOVE CALCULATIONS				\$840.00
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28.)				\$0.00
SUBTOTAL				\$840.00
Processing fee of \$130 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(f))				\$0.00
TOTAL NATIONAL FEE				\$840.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).				\$0.00
TOTAL FEES ENCLOSED				\$840.00
			Amount to be refunded	
			Charged	
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$840.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.</p>				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO:				
Janis K. Fraser, Ph.D., J.D. FISH & RICHARDSON P.C. 225 Franklin Street Boston, MA 02110-2804 (617) 542-5070 phone (617) 542-8906 facsimile		 SIGNATURE Janis K. Fraser, Ph.D., J.D. NAME 34,819 REGISTRATION NUMBER		

## SPECIFICATION

METHOD FOR SCREENING FULL-LENGTH cDNA CLONES5 Technical field

The present invention belongs to the field of genetic engineering, and relates to a method for screening full-length cDNA clones.

Background Art

10 Recently, genome projects targeting various animals, plants, and microorganisms have been in progress. Numerous genes have been isolated and their functions are under investigation. In order to efficiently analyze the functions of isolated genes, it is important to efficiently obtain cDNA clones capable of expressing complete proteins, that is, full-length cDNA clones.

15 The followings are known as methods for constructing a full length-enriched cDNA library: the oligo capping method in which an RNA linker is enzymatically bound to Cap of mRNA (Sugano & Maruyama, Proteins, Nucleic Acids and Enzymes, 38: 476-481, 1993, Suzuki & Sugano, Proteins, Nucleic Acids and Enzymes, 41: 603-607, 1996, M. Maruyama and S. Sugano, Gene, 138, 171-174, 1994); the modified oligo capping method developed by combining the oligo capping method with Okayama-Berg method (S. Kato et al., Gene, 150, 243-250, 1994, Kato & Sekine, Unexamined Published Japanese Patent Application (JP-A) NO. Hei 6-153953, published June 3, 1994); and the linker chemical-binding method in which a DNA linker is bound to Cap (N. Merenkova and D. M. Edwards, WO 96/34981 Nov. 7, 1996), the cap chemical modification method by biotin modification of Cap (P. Carninci et al., Genomics, 37, 327-336, 1996, P. Carninci et al., DNA Research, 4, 61-66, 1997). These are all methods to modify Cap of eukaryotic mRNA and to prepare a full length-enriched cDNA library. A known method for constructing a full length-enriched cDNA library by trapping Cap is the method using Cap-binding proteins derived from yeast or Hela cells for labeling a 5'-cap site (I. Edery et al., MCB, 15, 3363-3371, 1995). Also known is Cap Finder (Clontech) that is the Cap Switch oligonucleotide method in which the Cap Switch oligonucleotide is annealed by C-tailing the 5' end of a first strand cDNA.

25

30

A cDNA library constructed by these methods is rich in full-length cDNAs compared to that obtained by the conventional methods. However, incomplete-length clones are also contained to some extent. To efficiently analyze the functions of genes and to efficiently clone novel useful genes, development of methods for easily confirming whether each clone contained in a cDNA library is full-length or not has been desired.

#### Disclosure of the Invention

An objective of the present invention is to provide a method for efficiently screening full-length cDNA clones, and a method for constructing a full length-enriched cDNA library.

The present inventors have studied to achieve the above objective and contemplated efficiently screening full-length cDNAs from a cDNA library by the presence or absence of a translation initiation codon as an index based on the fact that a cDNA deficient in a certain 5'-region is likely to lack a translation initiation codon, whereas a full-length cDNA contains an initiation codon. Specifically, the inventors assumed that a full-length cDNA could be efficiently screened from a cDNA library constructed by a method for preparing a full length-enriched cDNA library. Specifically, the inventors thought that full-length cDNA clones could be efficiently isolated by constructing a cDNA library by a method for preparing a full length-enriched cDNA library, determining several hundreds of base pairs of a DNA nucleotide sequence from the 5' end, and analyzing the presence or absence of an initiation codon in this region to screen the clones containing initiation codons.

However, few programs for predicting an initiation site of cDNA have been developed (e.g., "A. G. Pedersen, Proceedings of fifth international conference on intelligent systems for molecular biology, p226-233, 1997, held in Halkidiki, Greece, June 21-26, 1997). Though some programs for exons prediction have been developed ("Gene Finder". V. V. Solovyev et al., Nucleic Acids Res., 22, 5156-5163, 1994, "Grail" Y. Xu et al., Genet-Eng-N-Y., 16, 241-253, 1994), an initiation site cannot be accurately determined relying solely on these programs.

The present inventors have developed a program for cDNA initiation codon prediction by themselves and determined nucleotide sequences of the 5'-region of clones contained in a cDNA library constructed by a method for preparing a full

length-enriched cDNA library to examine whether an initiation codon exists in this 5'-region using this software program.

More specifically, a full length-enriched cDNA library was constructed by the oligo capping method and nucleotide sequences of the 5'-regions of some clones contained in the cDNA library were determined. Based on the determined sequences, the clones were divided into known and novel ones through a database search. The presence or absence of an initiation codon and its location in the determined nucleotide sequences of the 5'-regions were judged using the initiation codon prediction program. For the known clones, whether the location of the initiation codon recognized by the initiation codon prediction program coincides with that of the initiation codon in databases is examined. Indeed, the presence or absence and location of the initiation codon in the known clones predicted by the program coincided with the information in the databases.

Thus, the software program developed by the present inventors can accurately recognize the presence or absence of an initiation codon and its location, and full-length cDNA clones can be efficiently screened by selecting the clones that are recognized to contain an initiation codon by the program from the cDNA library. Moreover, a cDNA library extremely rich in full-length cDNAs can be constructed by combining the screened clones.

The present invention relates to a method for screening full-length cDNA clones from a cDNA library and a method for constructing a full-length cDNA library by combining cDNA clones screened by the screening method. More specifically, it relates to:

(1) A method for isolating a full-length cDNA clone, the method comprising:

(a) determining a nucleotide sequence from the 5'-region of a cDNA clone contained in a cDNA library,

(b) determining the presence or absence of an initiation codon in the nucleotide sequence determined in (a) using an initiation codon prediction program, and

(c) selecting clones recognized as containing the initiation codon in (b);

(2) The method of (1), wherein the cDNA library is constructed by a method for preparing a full length-enriched cDNA library;

(3) The method of (1), wherein a cDNA library is constructed by a method

comprising a step of modifying Cap of mRNA;

(4) A method for constructing a full length cDNA library, the method comprising:

(a) determining a nucleotide sequence from the 5'-region of a cDNA clone contained in a cDNA library,

(b) determining the presence or absence of an initiation codon in the nucleotide sequence determined in (a) using an initiation codon prediction program,

(c) selecting clones recognized as containing the initiation codon in (b), and

(d) combining the clones selected in (c);

(5) The method of (4), wherein the cDNA library is prepared by a method for constructing a full length-enriched cDNA library;

(6) The method of (4), wherein the cDNA library is constructed by a method comprising a step of modifying Cap of mRNA; and

(7) A cDNA library obtainable by the method of (4).

The present invention is based on the inventors' findings that full-length cDNA clones can be efficiently isolated by analyzing nucleotide sequences of the 5'-region of cDNAs in a cDNA library, specifically a full length-enriched cDNA library, by using a software program for accurately predicting a translation initiation codon, and a full length-enriched cDNA library can be constructed by combining the isolated cDNA clones. The method for screening full-length cDNA clones by the present invention comprises (a) determining a nucleotide sequence from the 5'-region of a cDNA clone contained in a cDNA library, (b) determining the presence or absence of an initiation codon in the determined nucleotide sequence using an initiation codon prediction program, and (c) selecting clones recognized as containing the initiation codon. The method for constructing a full-length cDNA library of the present invention comprises, in addition to above steps (a) to (c), step (d) of combining the screened clones.

In the method of the present invention, a "cDNA clone" whose nucleotide sequence of the 5'-region is to be determined is not particularly limited. Full-length cDNAs cannot be efficiently isolated from clones derived from a library not rich in full-length cDNAs, compared with clones derived from a full length-enriched cDNA library. Therefore, a cDNA clone is preferably derived from a library

constructed by the above-described methods for preparing a full length-enriched cDNA library, including, for example, the oligo capping method in which an RNA linker is enzymatically bound to Cap of mRNA (Sugano & Maruyama, *Proteins, Nucleic Acids and Enzymes*, 38: 476-481, 1993, Suzuki & Sugano, *Proteins, Nucleic Acids and Enzymes*, 41: 603-607, 1996, M. Maruyama and S. Sugano, *Gene*, 138, 171-174, 1994), the modified oligo capping method developed by combining the oligo capping method with Okayama-Berg method (S. Kato et al., *Gene*, 150, 243-250, 1994, Kato & Sekine, JP-A-Hei 6-153953, June 3, 1994), the linker chemical-binding method in which a DNA linker is chemically bound to Cap (N. Merenkova and D. M. Edwards, WO 96/34981 Nov. 7, 1996), the Cap chemical modification method in which Cap is modified with biotin (P. Carninci et al., *Genomics*, 37, 327-336, 1996, P. Carninci et al., *DNA Research*, 4, 61-66, 1997), the method using Cap binding proteins derived from yeast or Hela cells (I. Edery et al., *MCB*, 15, 3363-3371, 1995), or a library prepared by Cap Finder using Cap Switch oligonucleotide method.

A cDNA clone can be isolated from a cDNA library by standard methods described in, for example, J. Sambrook, E. F. Fritsch & T. Maniatis, *Molecular Cloning*, Second Edition, Cold Spring Harbor Laboratory Press, 1989.

A nucleotide sequence can be determined from the 5'-region of a clone by, for example, standard methods using DNA sequencing reagents and a DNA sequencer available from Applied Biosystems, etc. A whole nucleotide sequence of the clone does not have to be determined, and determining about 1,000 nucleotides from the 5' end is sufficient. The high accuracy can be expected by determining about 500 nucleotides, even about 300 nucleotides.

An "initiation codon prediction program" used for analyzing a nucleotide sequence from the 5'-region of a clone is preferably the program developed by the present inventors as described in Example 1 below. The presence or absence of an initiation codon in a determined sequence is judged by a score deduced from the results of analysis with the program. A cDNA clone with a high score, recognized as containing an initiation codon in the determined sequence, is usually comprised of a full-length cDNA, while one with a low score, recognized as not containing an initiation codon in the determined sequence, contains an incomplete-length cDNA. Thus, a full-length cDNA can be efficiently isolated by screening a cDNA from a

cDNA library, judged as containing an initiation codon in the nucleotide sequence. Indeed, in one embodiment of the analysis with the program described in Example 1 below where a cDNA library with the full-length cDNA content of 51% was used to screen clones (the highest score was 0.94), the content of full-length clones among the screened clones was 71% when clones showing a score of 0.5 or higher were selected, 77% with a score of 0.70 or higher, 81% with a score of 0.80 or higher, and 85% with a score of 0.90 or higher. Therefore, full-length cDNA clones can be screened with a high accuracy by selecting clones with high scores using the program described in Example 1.

Moreover, a cDNA library re-constructed by combining clones selected by the method for screening full-length cDNA clones of the present invention is extremely rich in full-length cDNAs compared with the parent cDNA library used for screening clones. By expressing whole cDNAs capable of expressing proteins in the thus-obtained library, a system for efficiently analyzing gene functions containing a mixture of expressed proteins can be obtained. This system enables efficiently cloning useful genes.

#### Best Mode for Carrying out the Invention

The present invention is illustrated in detail below with reference to the following examples, but is not to be construed as being limited thereto.

#### Example 1. Preparation of a program for predicting a translation initiation codon of cDNA

The translation initiation codon prediction program of the present invention recognizes a putative authentic initiation codon among all ATGs contained in a given cDNA sequence fragment. The program predicts based on A) information on similarity of given regions (several tens to several hundreds base pairs) at both sides of a putative ATG to translational regions and B) information on similarity of regions near a putative ATG to those near an authentic initiation codon. Characteristics of sequences in a translational region and regions near an initiation codon are extracted beforehand by from information of numerous sequences whose translational and non-translational regions have been identified. The program predicts an initiation codon based on the information about the above



characteristics.

The linear discriminant analysis used in Gene Finder, a program for genomic exon prediction (Solovyev V. V., Salamov A. A., Lawrence C. B. Predicting internal exons by oligonucleotide composition and discriminant analysis of spliceable open reading frames. *Nucleic. Acids Res*, 1994, 22: 5156-63), was applied to optimize prediction. In the linear discriminant analysis, information on some characteristics derived from data is digitized, weighted, and then culculated a score. Here, a score is converted into a probability of similarity to an initiation codon (the probability is a rate of correct answers obtained from data of sequences whose initiation codon has been identified). Specifically, a probability of similarity to an initiation codon of each ATG contained in a given cDNA sequence is output. Recognition as an initiation codon is determined whether a probability of similarity to an initiation codon is above a given threshold value or not. A threshold value is established depending on the plan of the following analyses, that is, depending on the extent of noises acceptable for the following analysis. For example, when 40% of noise is acceptable, a threshold value of 0.6 can be used. A parameter of weight is determined so as to maximize the prediction system using data of sequences whose initiation codon has been identified as a training datum. The above information of A) and B) were each embodied into the following three information and used as information about characteristics.

A) information on similarity of given regions (several tens to several hundreds base pairs) at both sides of a putative ATG to translational regions

- 1: a frequency of six nucleotide base letters contained in a sequence from ATG to a stop codon (within 300 bp downstream of ATG at longest)
- 2: discrepancy of the information on a frequency of six nucleotide base letters contained in 50 nucleotide bases upstream and downstream of ATG
- 3: an index of similarity to a signal peptide [a hydrophobicity index of the most hydrophobic eight amino acids letters among 30 amino acids (90 nucleotide bases) downstream of ATG]

B) information on similarity of regions near a putative ATG to those near an authentic initiation codon

- 1: information on a weighted matrix as using three nucleotide base letters in the region from 14 nucleotide bases upstream of ATG to 5 nucleotide

bases downstream of ATG as a unit

2) the presence or absence of other ATGs upstream of ATG in a same frame  
(the presence is 1 and the absence is 0)

3: a frequency of cytosine contained in the region from 36 bases upstream of  
ATG to 7 bases downstream of ATG.

Example 2: Preparation of cDNA by the oligo capping method and analysis thereof  
by the program for initiation codon prediction

A cDNA library was prepared by the oligo capping method and the plasmid  
DNA was extracted from each clone by the standard method. Specifically, mRNA  
was extracted from human placenta and human cultured cells (Tetratocarcinoma  
NT-2 and neuroblastoma SK-N-MC) by the method described in the reference (J.  
Sambrook, E. F., Fritsch & T. Maniatis, Molecular Cloning, Second Edition, Cold  
Spring Harbor Laboratory Press, 1989). An oligo cap linker (SEQ ID NO. 1) with  
an oligo dT adaptor primer (SEQ ID NO. 2) in the case of Tables 1 & 2, or with a  
random adaptor primer (SEQ ID NO. 3) in the case of Tables 3 & 4 were subjected  
to BAP treatment, TAP treatment, RNA ligation, synthesis of a first strand cDNA,  
and removal of RNA according to the methods described in the references (Suzuki  
& Sugano, Proteins, Nucleic Acids, and Enzymes, 41, 603-607, 1996, p606, Y.  
Suzuki et al., Gene, 200, 149-156, 1997). The first strand cDNA was then  
converted into the double-stranded DNA by PCR, digested with *Sfi*I, and cloned  
into vectors, such as pME18SCG, pMFL etc. digested with *Dra*III in the determined  
direction (Sugano & Maruyama, Proteins, Nucleic Acids, and Enzymes, 38, 472-481,  
1993, p480). The obtained DNA was subjected to the sequencing reaction using a  
DNA sequencing reagent (DyeTerminator Cycle Sequencing FS Ready Reaction  
Kit, PE Applied Biosystems) following the manual and sequenced with a DNA  
sequencer (ABIPRISM 377, PE Applied Biosystems). The DNA sequence of the 5'-  
region of each clone was analyzed once.

The presence or absence of an initiation codon in the DNA sequence of each  
clone was analyzed using the developed program for cDNA initiation codon  
prediction (ATGpr). In this analyzing program, the higher the score is, the higher  
the probability of being an initiation codon is. The maximum score is 0.94.

(1) Analysis of translation initiation codons in the clones whose open reading frames are known in database among cDNA prepared by the oligo capping method

Among the results for all analyzed clones, the result for the clones that are known to contain the initiation codon in the determined sequences in databases (F-NT2RP1000020, F-NT2RP1000025, F-NT2RP1000039, and F-NT2RP1000046) are shown in Table 1. F-NT2RP1000020 (880 bp) has 96% identity at nucleotide positions 88 to 690 to "human neuron-specific gamma-2 enolase" (GenBank accession No. M22349); F-NT2RP1000025 (645 bp), 97% homology at positions 29 to 641 to "human alpha-tubulin mRNA" (GenBank accession No. K00558); F-NT2RP1000039 (820 bp), 96% identity at positions 12 to 820 to "human mRNA for elongation factor 1 alpha subunit (EF-1 alpha) (GenBank accession No. X03558); and F-NT2Rp1000046 (788 bp), 97% identity at positions 3-788 to "human M2-type pyruvate kinase mRNA" (GenBank accession No. M23725). The sequences of the 5'-region in these clones are shown in SEQ ID Nos: 4, 5, 6, and 7.

Table 1

F-NT2RP1000020			F-NT2RP1000025		F-NT2RP1000039		F-NT2RP1000046	
ATG No.	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score
1	1	0.05	96	<0.94>	65	<0.90>	111	<0.94>
2	162	<0.84>	148	0.13	154	0.05	174	0.82
3	292	0.05	193	0.05	209	0.11	198	0.19
4	313	0.05	201	0.09	231	0.05	300	0.16
5	441	0.05	232	0.05	321	0.05	315	0.11

Note 1: <> means translation initiation codon

Note 2: Location of ATG means the nucleotide base position of ATG in the 5'-region of a DNA sequence.

ATG No. means the number of ATG from the 5'-region of a DNA sequence.

As show in Table 1, among the cDNA prepared by the oligo capping method, the full-length clones whose open reading frames are known in databases, containing initiation codons were accurately recognized by the initiation codon prediction program (ATGpr) (coincident with the initiation codons in databases).

(2) Analysis of initiation codons in the clones whose open reading frames are known in database among cDNA prepared by the oligo capping method

Among the results for the clones analyzed, the results for the clones whose initiation codon is known to absent in the determined sequence in databases (F-NT2RP1000013, F-NT2RP1000054, and F-NT2RP1000122) are shown in Table 2. F-NT2RP1000013 (608 bp) has 97% identity at positions 1 to 606 to "human nuclear matrix protein 55 (nmt55) mRNA" (GenBank accession No.U89867); F-NT2RP1000054 (869 bp), 96% identity at positions 1 to 869 to "human signal recognition particle (SRP54) mRNA" (GenBank accession No. U51920); and F-NT2RP1000122 (813 bp), 98% identity at positions 1 to 813 to "*H. sapiens* mRNA for 2-5A binding protein" (GenBank accession No. X76388). The sequences of the 5' region of these clones are shown in SEQ ID Nos: 8, 9, and 10.

Table 2

F-NT2RP1000013			F-NT2RP1000054		F-NT2RP1000122	
ATG No.	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score
1	21	0.05	31	0.12	23	0.07
2	27	0.05	60	0.20	100	0.05
3	32	0.32	87	0.05	166	0.05
4	56	0.11	97	0.05	235	0.06
5	119	0.10	146	0.05	316	0.05
6	125	0.08	172	0.05	346	0.05
7	141	0.05	180	0.11	406	0.05
8	155	0.06	218	0.07	431	0.05
9	161	0.06	272	0.05	469	0.06
10	176	0.08	319	0.07	546	0.12
11	203	0.07	346	0.05	553	0.05
12	290	0.20	363	0.07	574	0.05
13	311	0.16	409	0.05		
14	314	0.12	480	0.07		

As shown in Table 2, among cDNA prepared by oligo capping method, the

initiation codon prediction program (ATGpr) did not recognize by mistake the initiation codons in incomplete-length cDNAs whose open reading frames are known in databases and which do not contain any initiation codons.

(3) Analysis of initiation codons in novel clones among the cDNA prepared by the oligo capping method

Among the results for analyzed clones, the results for novel clones that were predicted to contain initiation codons (F-ZRV6C1000408, F-ZRV6C1000454, F-ZRV6C1000466, F-ZRV6C1000615, and F-ZRV6C1000670) are shown in Table 3. The sequences of the 5' region of these clones are shown in SEQ ID Nos: 11, 12, 13, 14, 15.

Table 3

F-ZRV6C1000408			F-ZRV6C1000454		F-ZRV6C1000466	
ATG No.	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score
1	85	<0.94>	5	0.05	162	<0.86>
2	208	0.22	107	<0.87>	182	0.05
3	386	0.05	153	0.05	207	0.08
4	518	0.11	201	0.08	244	0.05
5	545	0.05	211	0.05	262	0.05
6			236	0.07	303	0.11

(cont'd)

Table 3 (cont'd)

F-ZRV6C1000615			F-ZRV6C1000670	
ATG No.	Location of ATG	ATGpr Score	Location of ATG	ATGpr Score
1	85	<0.94>	120	<0.94>
2	208	0.26	187	0.54
3	386	0.05	312	0.06
4	518	0.09	388	0.05
5	545	0.05	445	0.05

Note: <> means predicted initiation codon.

As shown in Table 3, the predicted initiation codons in F-ZRV6C1000408, F-ZRV6C1000454, F-ZRV6C1000466, F-ZRV6C1000615, and F-ZRV6C1000670 are "ATG" starting with "A" at positions 85, 107, 162, 85, and 120, respectively. Therefore, these clones were judged as full-length cDNA clones.

In addition, among the results for analyzed clones, the results for novel clones predicted as not containing initiation codons (F-ZRV6C1001410, F-ZRV6C1001197, and F-ZRV6C1001472) are shown in Table 4. The sequences of the 5' region of these clones are shown in SEQ ID Nos: 16, 17 and 18.

Table 4

F-ZRV6C1001410			F-ZRV6C1001197		F-ZRV6C1001472	
ATG Location	ATGpr		Location	ATGpr	Location	ATGpr
No. of ATG	Score		of ATG	Score	of ATG	Score
1	23	0.05	5	0.24	77	0.25
2	31	0.07	141	0.25	126	0.05
3	71	0.06	202	0.05	149	0.05
4	178	0.05	219	0.05	194	0.05
5	214	0.05	228	0.05	213	0.22
6					249	0.05
7					338	0.09
8					344	0.05
9					351	0.05
10					365	0.05

As shown in Table 4, F-ZRV6C1001410, F-ZRV6C1001197, and F-ZRV6C1001472 were recognized as not containing initiation codons. These clones were thus judged as incomplete-length clones.

### Industrial Applicability

The present invention provides a method for efficiently selecting full-length cDNAs. Clones selected by the method of the present invention can express complete proteins. Therefore, the present invention enables efficiently analyzing the functions of isolated genes.

## CLAIMS

1. A method for isolating a full-length cDNA clone, the method comprising:
  - (a) determining a nucleotide sequence from the 5'-region of a cDNA clone  
5 contained in a cDNA library;
  - (b) determining the presence or absence of an initiation codon in the nucleotide sequence determined in (a) using an initiation codon prediction program; and
  - (c) selecting clones recognized as containing the initiation codon in (b).
- 10 2. The method of claim 1, wherein the cDNA library is constructed by a method for preparing a full length-enriched cDNA library.
3. The method of claim 1, wherein a cDNA library is constructed by a method comprising a step of modifying Cap of mRNA.
- 15 4. A method for constructing a full length cDNA library, the method comprising:
  - (a) determining a nucleotide sequence from the 5'-region of a cDNA clone contained in a cDNA library;
  - (b) determining the presence or absence of an initiation codon in the nucleotide sequence determined in (a) using an initiation codon prediction program;
  - 20 (c) selecting clones recognized as containing the initiation codon in (b); and
  - (d) combining the clones selected in (c).
5. The method of claim 4, wherein the cDNA library is prepared by a method for constructing a full length-enriched cDNA library.
6. The method of claim 4, wherein the cDNA library is constructed by a  
25 method comprising a step of modifying Cap of mRNA.
7. A cDNA library obtainable by the method of claim 4.

### Abstract

A method for efficiently screening full-length cDNA clones, the method comprising determining a nucleotide sequence of the 5'-region of a clone contained  
5 in a cDNA library prepared by a method for constructing a full length-enriched cDNA library and examining the presence or absence and the location of a translation initiation codon in the 5'-region using an originally developed program for predicting initiation codons in cDNA. This originally developed program accurately predicts the presence or absence and the location of initiation codons and  
10 efficiently screens full-length cDNA clones by selecting clones judged as containing an initiation codon from a cDNA library. Moreover, a cDNA library extremely rich in full-length cDNAs can be constructed by combing the selected clones.



416 Rec'd PCT/PTO 20 APR 2000

## SEQUENCE LISTING

<110> Helix Research Institute, Inc.

<120> Method for screening full-length cDNA clones

<130> H1-806PCT

<150> JP 09-289982

<151> 1997-10-22

<160> 18

<170> PatentIn version 2.0

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligo-capping linker sequence

<400> 1

AGCAUCGAGU CGGCCUUGUU GGCCUACUGG

30

<210> 2

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligo(dT) adapter primer sequence

<400> 2

GCGGCTGAAG ACGGCCTATG TGGCCTTTT TTTTTTTTTT TT

42

&lt;210&gt; 3

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Random adapter primer sequence

&lt;400&gt; 3

GCGGCTGAAG ACGGCCTATG TGGCCNNNN NC

32

&lt;210&gt; 4

&lt;211&gt; 880

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

ATGCGCCCGC GCGGCCCTAT AGGCGCCTCC TCCGCCCGCC GCCCGGGAGC CGCAGCCGCC 60  
 GCCGCCACTG CCACTCCCGC TCTCTCAGCG CCGCCGTCGC CACCGCCACC GCCACTGCCA 120  
 CTACCACCGT CTGAGTCTGC AGTCCCGAGA TCCCAGCCAT CATGTCCATA GAGAAGATCT 180  
 GGGCCCGGGA GATCCTGGAC TCCCGCGGGA ACCCCACAGT GGAGGTGGAT CTCTATACTG 240  
 CCAAAGGTCC TTTCCGGGCT GCAGTGCCCA GTGGAGCCTC TACGGGCATC TATGAGGCCC 300  
 TGGAGCTGAG GGATGGAGAC AAACAGCGTT ACTTAGGCAA AGGTGTCCTG AAGGCAGTGG 360  
 ACCACATCAA CTCCACCATC GCGCCAGCCC TCATCAGCTC AGGTCTCTCT GTGGTGGAGC 420  
 AAGAGAAACT GGACAACCTG ATGCTGGAGT TGGATGGGAC TGAGAACAAA TCCAAGTTTG 480  
 GGGCCAATCC ATCCTGGGTG TGTCTCTGGC CGTGTGTAAG GCANGGGCAA CTGAACNGGA 540  
 ACTGCCCTG TATCGCCACA TTGCTCAGCT TGGNCGGGA CTCANACCTC ATCCTGCCTG 600  
 TTGCCGGCCT TCAACGTGAT CAATGGTTGG CTTCTCATGC CTGGCAACAA ANCTGGCCAT 660  
 TGCNGGAATT TTCATGATCC TCCCNTTGG GAAACTGAAA AACTTTCCGG AATGCCCNTC 720  
 CAACTAAGTT GCAAAAGGTC TACCNATACC CCCCAGGGG AATTCCTCCA AGGGAACAAA 780  
 TNCCCGGGAA AGGAATGCC CCCAATTNT NGGGGAATA AAAGGTGGGC TTTGCCCCC 840  
 CATTTTCCTG GAAAAACNA TNAACCCT TGGGAACTT 880

&lt;210&gt; 5

&lt;211&gt; 645

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

```

TGTGCGTTAC TTACCTCNAC TCTTAGCTTG TCGGGGACGG TAACCGGGAC CCGGTGTCTG   60
CTCCTGTGCG CTTCGCCTCC TAATCCCTAG CCACTATGCG TGAGTGCATC TCCATCCACG  120
TTGGCCAGGC TGGTGTCCAN ATTGGCAATG CCTGCTGGGA GCTCTACTGC CTGGAACACG  180
GCATCCAGCC CGATGGCCAG ATGCCAAGTG ACAAGACCAT TGGGGGAGGA GATGACTCCT  240
TCAACACCTT CTTCAGTGAG ACGGGCGCTG GCAANCACGT GCCCGGGCT GTGTTTGTAG  300
ACTTGAACC CACAGTCATT GATGAAGTTC GCACTGGCAC CTACCGCCAG CTCTCCACC  360
CTGAGCAGCT CATCNCAGGC AAGGAAGATG CTGCCAATAA CTATGCCCGA GGGCACTACA  420
CCATTGGCAA GGAGATCATT GACCTTGTGT TGGACCGAAT TCGCAAGCTG GCTGACCANT  480
GCACCGGTCT TCANGGCTTC TTGGTTTCC ACAGCTTTGG TGGGGGAACT GGTTCGGGT  540
TCACCTCCCT GCTCATGGAA CGTCTCTCAG TTGATTATGG CAAGAAATCC AAGCTGGAGT  600
TCTCCATTTA CCCAGCACCC CNGGTTCCN CNGCTGTANT TNGAA                      645

```

&lt;210&gt; 6

&lt;211&gt; 820

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

```

CTTTTTTCGC AACGGGTTTG CCGCCAGAAC ACAGGTGTGC TGAAACTAC CCCTAAAAGC   60
CAAAATGGGA AAGGAAAAGA CTCATATCAA CATTGTCGTC ATTGGACACG TAGATTCGGG  120
CAAGTCCACC ACTACTGGCC ATCTGATCTA TAAATGCGGT GGCATCGACA AAAGAACCAT  180
TGAAAAATTT GAGAAGGAGG CTGCTGAGAT GGGAAAGGGC TCCTTCAAGT ATGCCTGGGT  240
CTTGATAAAA CTGAAAGCTG AGCGTGAACG TGGTATCACC ATTGATATCT CCTGTGGAA  300
ATTTGAGACC AGCAAGTACT ATGTGACTAT CATTGATGCC CCAGGACACA GAGACTTTAT  360
CAAAAACATG ATTACAGGGA CATCTCAGGC TGAATGTGCT GTCCTGATTG TTGCTGCTGG  420
TGTTGGTGAA TTTGAAGCTG GTATCTCCAA GAATGGGCAG ACCCGAGAGC ATGCCCTTCT  480
GGCTTACACA CTGGGTGTGA AACAATAAT TGTCGGTGTT AACAAAATGG ATTCACTGAN  540
CCACCCTACA GCCAGAAGAA ATATGANGAA ATTGTTAAGG AAGTCAGCAC TTACATTAAG  600
AAAATTGGCT ACAACCCCGA CACAGTANCA TTTGTGCCAA TTTCTGGTTG GAATGGTGAC  660

```

AACATGCTGG AACCAANTGC TAACATGCCT TGGTTCCAGG GATGGAAAAT CCCCNTTAA 720  
 GGATGGCNAT GCCATTGGAA CCCCCTGCT TGAAGGCTCT GGANTGCATC CTANCACCAA 780  
 CTCCTTCAAA TTGAAAAACC CCTTGCNCCC GCCTCCNCCA 840

<210> 7

<211> 788

<212> DNA

<213> Homo sapiens

<400> 7

GAGGCTGAGG CAGTGGCTCC TTGCACAGCA GCTGCACGCG CCGTGGCTCC GGATCTCTTC 60  
 GTCTTTGCAG CGTAGCCCGA GTCGGTCAGC GCCGGAGGAC CTCAGCAGCC ATGTCGAAGC 120  
 CCCATAGTGA AGCCGGGACT GCCTTCATTC AGACCCAGCA GCTGCACGCA GCCATGGCTG 180  
 ACACATTCCT GGAGCACATG TGCCGCCTGG ACATTGATTC ACCACCCATC ACAGCCCGGA 240  
 ACACTGGCAT CATCTGTACC ATTGGCCCAG CTCCCGATC AGTGGAGACG TTGAAGGAGA 300  
 TGATTAAGTC TGGAATGAAT GTGGCTCGTC TGAAC TTCTC TCATGGAACT CATGAGTACC 360  
 ATGCGGAGAC CATCAAGAAT GTGCGCACAG CCACGGAAAG CTTTGCTTCT GACCCCATCC 420  
 TCTACCGGCC CGTTGCTGTG GCTCTAGACA CTAAAGGACC TGAGATCCGA ACTGGGCTCA 480  
 TCAAGGGCAG CGGCACTGCA GAGGTGGAGC TGAAGAATGG AGCCACTCTC AAAATCACGC 540  
 TGGATAATGC CTACATGGAA AAGTGTGACG AGAACATCCT GTGGCTGGAC TACAAGAACA 600  
 TCTGCAAGGT GGTGGAAGTG GGCAACAAGA TCTACGTGGA TGATGGGCTN ATTTCTCTCC 660  
 AGGTGAACAC AAAGGTGCCG ACTTCCTGGG TGACNGANGT GGAAAATGGT GGCTCCTTGG 720  
 GCNCAAGAAA GGTGTGAACT TCCTGGGGCT GCTGTGGANT TGCCTGCTGT GTCNGAAAAA 780  
 GACATCCA 788

<210> 8

<211> 608

<212> DNA

<213> Homo sapiens

<400> 8

ACAGCCTGGC TCCTTTGAGT ATGAATATGC CATGCGCTGG AAGGCACTCA TTGAGATGGA 60  
 GAAGCAGCAG CAGGACCAAG TGGACCGCAA CATCNAGGAG GCTCGTGAGA AGCTGGAGAT 120  
 GGAGATGGAA GCTGCACGCC ATGAGACCA GGTGATGCTA ATGAGACAGG ATTTGATGAG 180

GCGCCAAGAA GAACTTCGGA GGATGGAAGA GCTGCACAAC CAAGANGTGC AAAAACGAAA 240  
 GCAACTGGAG CTCAGGCAGG AGGAANAGCG CAGGCGCCGT GAAGANAGA TGCGGCGGCA 300  
 GCAAGAAGAA ATGATGCGGC GACNGCAGGA AGGATTCAAG GGAACCTTCC CTGATGCGAG 360  
 AGAGCAGGAG ATTCGGATGG GTCNGATGGC TATGGGAGGT GCTATGGGCA TAAACNACAG 420  
 ATGTGCCATG CCCCCTGCTC CTGTGCCAGC TGGTACCCCA GCTCCTCCAG GACCTGCCAC 480  
 TATTATGCCG GATGGAACCT TGGGATTGAC CCCACCNACA ACTGAACGCT TTGGTCNGGC 540  
 TGCTACNATG GAANGAATTG GGGCAATTGG TGGAACCTCT CCTGCATTCT ACCGTGCAGC 600  
 TCCTGGGA 608

<210> 9

<211> 869

<212> DNA

<213> Homo sapiens

<400> 9

ATATTAACT AGTGAAGCAA CTAAGAGAAA ATGTTAAGTC TGCTATTGAT CTTGAAGAGA 60  
 TGGCATCTGG TCTTAACAAA AGAAAAATGA TTCAGCATGC TGTATTTAAA GAACTTGTGA 120  
 AGCTTGTAGA CCCTGGAGTT AAGGCATGGA CACCCACTAA AGGAAAACAA AATGTGATTA 180  
 TGTTTGTGG ATTGCAAGGG AGTGGTAAAA CAACAACATG TTCAAAGCTA GCATATTATT 240  
 ACCAGAGGAA AGGTTGGAAG ACCTGTTTAA TATGTGCAGA CACATTCAGA GCAGGGGCTT 300  
 TTGACCAACT AAAACAGAAT GCTACCAAAG CAAGAATTCC ATTTTATGGA AGCTATACAG 360  
 AAATGGATCC TGTCATCATT GCTTCTGAAG GAGTAGAGAA ATTTAAAAAT GAAAATTTTG 420  
 AAATTATTAT TGTGATACA AGTGGCCGCC ACAAACAAGA AGACTCTTTG TTTGAAGAAA 480  
 TGCTTCAAGT TGCTAATGCT ATACAACCTG ATAACATTGT TTATGTGATG GATGCCTCCA 540  
 TTGGGCAGGC TTGTGAAGCC CAGGCTAAGG CTTTTAAAGA TAAAGTAGAT GTACCTCAGT 600  
 AATAGTGACA AACTTGATG GCCATGCAAA ANGAAGTGGT GCACTCAGTG CAGTCGCTGC 660  
 CACAAAAAAT CCGATTATTT TCATTGGTAC AGGGGGAACA TATANATGAC TTTGAACCTT 720  
 TCAAAAACAC AGCCTTTTAT TAACAACTT CTTGGTATNG GCGACATTGA AAGGACTGAT 780  
 AAATAAAGTC CACNAATTGA AATTTGGATG ACNATGNAAA CCCTTATTGA AAAAATTGAA 840  
 ACATNGTCCA GTTTTACTTT GCGAAACNT 869

<210> 10

<211> 813

<212> DNA

<213> Homo sapiens

<400> 10

GTTGTGGTAT CTGTATTAAG AAATGCCCTT TTGGCGCCTT ATCAATTGTC AATCTACCAA 60  
 GCAACTTGGA AAAAGAAACC ACACATCGAT ATTGTGCCAA TGCCTTCAA CTTACAGGT 120  
 TGCCTATCCC TCGTCCAGGT GAAGTTTGG GATTAGTTGG AACTAATGGT ATTGGAAAGT 180  
 CAACTGCTTT AAAAATTTTA GCAGGAAAAC AAAAGCCAAA CCTTGGAAG TACGATGATC 240  
 CTCCTGACTG GCAGGAGATT TTGACTTATT TCCGTGGATC TGAATTACAA AATTACTTTA 300  
 CAAAGATTCT AGAAGATGAC CTAAGGCCA TCATCAAACC TCAATATGTA GACCAGATTC 360  
 CTAAGGCTGC AAAGGGGACA GTGGGATCTA TTTTGGACCG AAAAGATGAA ACAAAGACAC 420  
 AGGCAATTGT ATGTCAGCAG CTTGATTTAA CCCACCTAAA AGAACGAAAT GTTGAAGATC 480  
 TTTTCAGGAGG AGAGTTGCAG AGATTTGCTT GTGCTGTCGT TTGCATACAG AAAGCTGATA 540  
 TTTTCATGTT TGATGAGCCT TCTAGTTACC TAGATGTCAA GCAGCGTTTA AAGGCTGCTA 600  
 TTAATAACG ATCTCTAATA AATCCAGATA GATATATCAT TGTGGTGGAA CATGATCTAA 660  
 GTGTATTAGA CTATCTCTCC GACTTCATCT GCTGTTTATA TGGTGTACCA AGCGCCTATG 720  
 GAATTGTCAC TATGCCTTTT AGTGTTAGAA AAGGCATAAA CNTTTTTTGG ATGGGTATGT 780  
 TCCAACAGAA AACTTGANAA TCNNAATGC NTC 813

<210> 11

<211> 655

<212> DNA

<213> Homo sapiens

<400> 11

AGACTCTCAC CGCAGCGGCC AGGAACGCCA GCCGTTACG CGTTCGGTCC TCCTTGGCTG 60  
 ACTCACCGCC CTCGCCGCG CACCATGGAC GCGCCAGGC AGGTGGTCAA CTTTGGGCCT 120  
 GGTCCCGCCA AGCTGCCGCA CTCAGTGTG TTAGAGATAC AAAAGGAATT ATTAGACTAC 180  
 AAAGGAGTTG GCATTAGTGT TCTTGAAATG AGTCACAGGT CATCAGATTT TGCCAAGATT 240  
 ATTAACAATA CAGAGAATCT TGTGCGGGAA TTGCTAGCTG TTCCAGACAA CTATAAGGTG 300  
 ATTTTCTGC AAGGAGGTGG GTGCGGCCAG TTCAGTGCTG TCCCCTTAAA CCTCATTTGGC 360  
 TTGAAAGCAG GAAGGTGTGC GGAATATGTG GTGACAGGAG CTTGGTCAGC TAAGGCCGCA 420  
 GAAGAAGCCA AGAAGTTTGG GACTATAAAT ATCGTTCACC CTAAGTTGG GAGTTATACA 480  
 AAAATTCCAG ATCCAAGCAC CTGGAACCTC AACCCANATG CCTCCTACGT GTTTTATTGC 540  
 NCAATGAAA CGGTGCATGG TGTGTANTTT GACTTTTATC CCNATGTCAA GGGAACANTA 600  
 CTGTTTGTG ACATTTTCCT CCAACTTCCT GTCCAANCCA ATTGNATGTT TCCAA 655

&lt;210&gt; 12

&lt;211&gt; 599

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

AAAGATGCCG AGGCGCCGTG TGGCACTCGG CGGTCGAAAG GGGAGTTCAA GGAGACGGGG 60  
 GCGACGCGGC TGAGGGCTTC TCGTCGGGGT CGGGGCTGCA GCCGTCATGC CGGGGATAGT 120  
 GGAGCTGCCC ACTCTAGAGG AGCTGAAAGT AGATGAGGTG AAAATTAGTT CTGCTGTGCT 180  
 TAAAGCTGCG GCCCATCACT ATGGAGCTCA ATGTGATAAG CCCAACAAGG AATTATGCT 240  
 CTGCCGCTGG GAANAGAAAG ATCCGAGGCG GTGCTTAGAG GAAGGCAAAC TGGTCAACAA 300  
 GTGTGCTTTG GACTTCTTTA GGCAGATAAA ACGTCACTGT GCAGAGCCTT TTACAGAATA 360  
 TTGGACTTGC ATTGATTATA CTGGCCAGCA GTTATTTCTG CACTGTGCGA AACAGCAGGC 420  
 AAAGTTTGAC NAGTGTGTGC TGGACAAACT GGGCTGGGTG CGGCCTGACC TGGGAAAAC 480  
 GTCAAAGGTC ACCAAAGTGA AAACAGATCN ACCTTTACCG GANAATCCCT ATCACTCAAG 540  
 AACAAGAACG GATCCCAGCC CTGANATCNA AGGAAATCTG CANCCTGCCA CACATGGCA 599

&lt;210&gt; 13

&lt;211&gt; 597

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

ATATCCGGAG TAGACGGAGC CGCAGTAGAC GGATCCGCGG CTGCACCAAA CACTGCCCCCT 60  
 CGGAGCCTGG TAGTGGGCCA CAAGCCCCCA GTCCCAGAGG CGTGATTTTC TGGCATCCTT 120  
 AAATCTTGTTG TCAAGGATTG GTTATAATAT AACCAGAAAC CATGACGGCG GCTGAGAACG 180  
 TATGCTACAC GTTAATTAAC GTGCCAATGG ATTCAGAAAC ACCATCTGAA ATTAGCTTAA 240  
 AAAATGATCT AGAAAAAGGA GATGTAAAGT CAAAGACTGA AGCTTTGAAG AAAGTAATCA 300  
 TTATGATTCT GAATGGTGAA AAATTCCTG GACTTCTGAT GACCATCATT CGTTTTGTGC 360  
 TACCTCTTCA GGATCACACT ATCAAGAAAT TACTTCTGGT ATTTTGGGAG ATTGTTCCCTA 420  
 AAACAACTCC AGATGGGAGA CTTTACATG AGATGATCCT TGTATGTGAT GCATACAGAA 480  
 AGGATCTTCA ACATCCTAAT GAATTTATTC NAAGGATCTA CTCTTCGTTT TCTTTGCAAA 540  
 TTGAAANAAA CANAATTGCT AAAACCTTTA ATGCCANCTA TNCCTGCATT TTTGGGA 597

&lt;210&gt; 14

&lt;211&gt; 634

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

```

AGACTCTCAC CGCAGCGGCC AGGAACGCCA GCCGTTACAG CGTTCGGTCC TCCTTGGCTG   60
ACTCACCGCC CTCGCCGCCG CACCATGGAC GCCCCCAGGC AGGTGGTCAA CTTTGGGCCT  120
GGTCCCGCCA AGCTGCCGCA CTCAGTGTG TTAGAGATAC AAAAGGAATT ATTAGACTAC  180
AAAGGANTTG GCATTAGTGT TCTTGAAATG AGTCACAGGT CATCAGATTT TGCCAAGATT  240
ATTAACAATA CAGAGAATCT TGTGCGGGAA TTGCTAGCTG TTCCAGACAA CTATAAGGTG  300
ATTTTCTGCG AAGGAGGTGG GTGCGGCCAG TTCAGTGCTG TCCCCTTAAA CCTCATTGGC  360
TTGAAAGCAG GAANGTGTGC GGAATATGTG GTGACAGGAG CTTGGTCAGC TAAGGCCGCA  420
NAANAAGCCA AGAANTTTGG GACTATAAAT ATCGTTCACC CTAAACTTGG GAGTTATACA  480
AAAATTCCAG ATCCAAGCAC CTGGAACCTC AAGCCAGATG CCTCCTACGT GTATTATTGC  540
GCNAATGAAA CNGTGCATGG TGTGGANTCT GACTTTATAC CCGATGTCNA GGAACATAC  600
TGGTTTGTGA CATGTCCTCA AACTTCCCGT CCNA                                634

```

&lt;210&gt; 15

&lt;211&gt; 757

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

```

AGTCTGCGGT GGGCTANCGG ACGGTCCGGC TTCCGGCGGC CGTTTCTGTC TCTTGCTGGC   60
TGTCTCGCTG AATCGCGGCC GCCTTCTCAT CGCTCCTGGA AGGTCCCGAG CGCGACACCA  120
TGTCGGAACC CGGGGGCGGC GCGGGCGAAG ACNGCTCGGC CGGATTGGAA GTGTCGGCCG  180
TGCANAATGT GCGGGACGTG TCGGTGCTGC ANAAGCACCT GCGCAAGCTG GTGCCGCTGC  240
TGCTGGAGGA CGGCGGCGAA GCGCCGGCCG CGCTGGAGGC GCGCTGGAG GAGAAGAGCG  300
CCCTGGAGCA GATGCGCAAG TTCCTTTCGG ACCCGCACGT CCACACGGTG CTGGTGGAGC  360
GCTCCACGCT CAAAGTGGAC GTCGGTGATG AAGGAGAAGA AGAAAAAGAA TTCATTTCCT  420
ATAACATCAA CNTAGACATT CACTATGGGG TTAAATCCAA TAGCTTGGA TTCATTAAAC  480
GTACTCCCGT GATTGATGCA GATAAACCGG TGTCTTCTCA NCTCCGGGTC CTTAACTCA  540

```



GTGAANACTC NCCCTACNAA AACTTTGCAT TCTTTCATTA ACAATGCAGT GGCTCCTTTT 600  
 TTTAANTCCT ACATTAAAAA ATCTGGCAAG GCAAACAGGG ATGGTGATAA AATGGCTCCT 660  
 TCCNTTGAAA AAAAAATTGC CGAACTCNAA ATNGGACTCC TTCCCTTGCA NCAAAATTTT 720  
 TGAAATTCCG GAAAATCANC CTGCCCAATT CCTCCCC 757

<210> 16

<211> 300

<212> DNA

<213> Homo sapiens

<400> 16

ATCATTTCCT TATTTATATT TCATGTTGGA ATGCTTAAAT CGATAACCTT TGTATTTTGA 60  
 AGTGCGCGAC ATGGAAGGTG ATCTGCAAGA GCTGCATCAG TCAAACACCG GGGGATAAAT 120  
 CTGGATTGTTG GTTCCGGCGT CAAGGTGAAG ATAATACCTA AAGAGGAACA CTGTAAAATG 180  
 CCAGAAGCAG GTGAANAGCA ACCACAAGTT TAAATGAAGA CAAGCTGAAA CAACGCAAGC 240  
 TGGTTTTATA TTAGATATTT GACTTAAACT ATCTCAATAA AGTTTTGCAG CTTTCACCAC 300

<210> 17

<211> 313

<212> DNA

<213> Homo sapiens

<400> 17

AAAGATGGCG GCGGGGGAGG TAGGCAGAGC AGGACGCCGC TGCTGCCGCC GCCACCGCCG 60  
 CCTCCGCTCC AGTCGCCTCC GGTCTTCAA ACTCACACCT CCCGGGAGGA GCTGTCCTGG 120  
 CGCCGGGTCC CGCGGGGAAA ATGGTGGAGC CAGGGCAAGA TTTACTGCTT GCTGCTTTGA 180  
 GTGAGAGTGG AATTAGTCCG AATGACTCTT TGATATTGAT GGTGGAGATG CANGGCTTGC 240  
 AACTCCAATG CCTACCCCGT CAGTTCAGCA NTCAGTGCCA CTTANTGCAT TANAACANG 300  
 TTTGGAGACC GAA 313

<210> 18

<211> 667

<212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ACTGCCGGGC TCGGCGTGAG TCGCTGCGGG GCTGACGGGG TGGCAGTGCG GCGGGTTACG 60  
GCCTGGTCAG ACCATAATGA CTCAGCAAA TAAAGCAATC GAATTACAAC TACAAGTGAA 120  
ACAAAATGCA GAAGAATTAC AAGACTTTAT GCGGGATTTA GAAAACTGGG AAAAAGACAT 180  
TAAACAAAAG GATATGGAAC TAAGAAGACA GAATGGTGTT CCTGAAGAGA ATTTACCTCC 240  
TATTCGAAAT GGAATTTTA GAAAAAGAA GAAAGGCAAA GCTAAAGAGT CTTCCCCAAA 300  
ACCANAGAGG AAAACACNAA AAACAGGATA AAATCTTATG ATTATGANGC ATGGGCAAAA 360  
CTTGATGTGG ACCGTATCCT TGATGAGCTT GACAAAGACG ATAGTACCCA TGAGTCTCTG 420  
TCTCAAGAAT CAGAGTCGGA AGAAGATGGG ATTCATGTTG ATTCNCNAAA GGCTCTTGTT 480  
TTAAAAGAAA AGGGCNATAA ATACTTCCAC AAGGAAAATA TGATGAAGCA ATTGACTGCT 540  
ACACNAAAGG CNTGGATGCC GATCCATATN ATCCCGTGTT GCCAACGAAC ANAACNTCCG 600  
CATATTTTAG ACTGAAAAAA TTTGCTGTTG CTGAATCTGA TTGTTATTAN CANTTGCCT 660  
TGAAATA 667

## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled METHOD FOR SCREENING FULL-LENGTH cDNA CLONES, the specification of which:

☐ is attached hereto.

☒ was filed on April 20, 2000 as Application Serial No. 09/529,962 and was amended on \_\_\_\_\_.

☐ was described and claimed in PCT International Application No. \_\_\_\_\_ filed on \_\_\_\_\_ and as amended under PCT Article 19 on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
Japan	9/289982	October 22, 1997	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
PCT	PCT/JP98/04772	October 21, 1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Janis K. Fraser, Reg. No. 34,819  
Timothy A. French, Reg. No. 30,175  
John T. Li, Reg. No. 44,210  
Ralph A. Mittelberger, Reg. No. 33,195

John W. Freeman, Reg. No. 29,066  
John F. Hayden, Reg. No. 37,640  
J. Peter Fasse, Reg. No. 32,983

Address all telephone calls to JANIS K. FRASER at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER at:

FISH & RICHARDSON P.C.  
225 Franklin Street  
Boston, MA 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Combined Declaration and Power of Attorney

Page 2 of 2 Pages

Full Name of Inventor: TOSHIO OTA

Inventor's Signature: Toshio Ota

Date: 11/17/00

Residence Address:

1-2-7-105, Tsujidou shinmachi

Fujisawa-shi

Kanagawa 251-0042 Japan JPX

Citizenship:

Japan

Post Office Address:

1-2-7-105, Tsujidou shinmachi

Fujisawa-shi

Kanagawa 251-0042 Japan

Full Name of Inventor: TETSUO NISHIKAWA

Inventor's Signature: Tetsuo Nishikawa

Date: 10/17/2000

Residence Address:

27-3-403, Hikawa-cho, Itabashi-ku

Tokyo 173-0013 Japan JPX

Citizenship:

Japan

Post Office Address:

27-3-403, Hikawa-cho, Itabashi-ku

Tokyo 173-0013 Japan

Full Name of Inventor: ASAF SALAMOV

Inventor's Signature: Asaf Salamov

Date: 27.09.2000

Residence Address:

36 Harvey Way

Saffron Walden

Essex CB10 2AP

United Kingdom GBX

Citizenship:

United Kingdom

Post Office Address:

36 Harvey Way

Saffron Walden

Essex CB10 2AP

United Kingdom

Full Name of Inventor: TAKAO ISOGAI

Inventor's Signature: Takao Isogai

Date: 10/3/00

Residence Address:

3-9-17-606, Kaibuchi, Kisarazu-shi

Chiba 292-0833 Japan JPX

Citizenship:

Japan

Post Office Address:

3-9-17-606, Kaibuchi, Kisarazu-shi

Chiba 292-0833 Japan

Applicant or Patentee: Toshio Ota et al  
 Serial or Patent No.: 09/529,962  
 Filed or Issued: April 20, 2000  
 For: METHOD FOR SCREENING FULL-LENGTH cDNA CLONES

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(f) and 1.27(c)) — SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: HELIX RESEARCH INSTITUTE  
 Address of Small Business Concern: 1532-3, Yana, Kisarazu-shi  
CHIBA 292-0812 JAPAN

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled METHOD FOR SCREENING FULL-LENGTH CDNA CLONES by inventor(s) TOSHIO OTA, TETSUO NISHIKAWA, ASAF SALAMOV AND TAKAO ISOGAI described in:

- ☐ the specification filed herewith.  
☒ application serial no. 09/529,962, filed April 20, 2000.  
☐ patent no.   , issued   .

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). \*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Full Name: \_\_\_\_\_

Address: \_\_\_\_\_

☐ INDIVIDUAL    ☐ SMALL BUSINESS CONCERN    ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status when any new rule 53 application is filed or prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.

Name:	Osamu Nagayama
Title:	Chief Executive Officer
Address:	1532-3, Yana, Kisarazu-shi CHIBA 292-0812 JAPAN

Signature: \_\_\_\_\_

Date: November 30, 2000